Norgine submits MAA to EMA for eflornithine in high-risk neuroblastoma: Netherlands Wednesday, January 8, 2025, 17:00 Hrs [IST] Norgine, a uniquely positioned, specialty pharmaceu ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback